MaxCyte, Inc. Repayments of Notes Payable
MaxCyte, Inc. (MXCT) reported Repayments of Notes Payable of $4.92 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-15.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfNotesPayable · last filed 2023-03-15
- MaxCyte, Inc. repayments of notes payable for the quarter ending 2021-12-31 was $0.00.
- MaxCyte, Inc. repayments of notes payable for the quarter ending 2021-09-30 was $0.00.
- MaxCyte, Inc. repayments of notes payable for the quarter ending 2021-06-30 was $0.00.
- MaxCyte, Inc. repayments of notes payable for the quarter ending 2021-03-31 was $4.92M.
- MaxCyte, Inc. repayments of notes payable for fiscal 2021 was $4.92M, a 241.83% increase from fiscal 2020.
- MaxCyte, Inc. repayments of notes payable for fiscal 2020 was $1.44M, a 71.80% decline from fiscal 2019.
- MaxCyte, Inc. repayments of notes payable for fiscal 2019 was $5.11M.
| Period end | Repayments of Notes Payable 3 month | Repayments of Notes Payable 6 month | Repayments of Notes Payable 9 month | Repayments of Notes Payable 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $0.00 derived: sum of 2 quarters · filed 2023-03-15 | $0.00 derived: sum of 3 quarters · filed 2023-03-15 | $4.92M 10-K · filed 2023-03-15 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $4.92M 10-Q · filed 2022-11-09 | $4.92M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $4.92M 10-Q · filed 2022-08-10 | $4.92M derived: sum of 3 quarters · filed 2022-08-10 | $4.92M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $4.92M 10-Q · filed 2022-05-09 | $4.92M derived: sum of 2 quarters · filed 2022-05-09 | $4.92M derived: sum of 3 quarters · filed 2022-05-09 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $0.00 derived: sum of 2 quarters · filed 2022-03-22 | $1.44M 10-K · filed 2022-03-22 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.44M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $1.44M 10-Q · filed 2021-09-13 | |||
| 2019-12-31 | $5.11M 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |